Literature DB >> 17591313

Recognizing and managing severe sepsis: a common and deadly threat.

Douglas Schlichting1, Jill Shwed McCollam.   

Abstract

Through a literature review, the epidemiology and pathophysiology, including alterations in inflammation, coagulation, and impaired fibrinolysis that occur in the course of severe sepsis, is presented. Treatment guidelines that are evidence-based and endorsed by 11 professional societies representing multispecialty groups are described. Severe sepsis is common; 750,000 cases are estimated to occur annually in the United States. The mortality rate for severe sepsis still ranges from 30 to 50%, and is as high as 80 to 90% for septic shock and multiple organ dysfunction. Severe sepsis exists along a continuum initiated by a localized infection that triggers a systemic response. A cascade of inflammation and activation of the coagulation system associated with impaired fibrinolysis leads to alterations in microvascular circulation associated with organ dysfunction, severe sepsis, multiple organ dysfunction syndrome, and death. In an attempt to improve care and reduce mortality, the Surviving Sepsis Campaign and The Institute for Healthcare Improvement (IHI) have created two sepsis treatment bundles.

Entities:  

Mesh:

Year:  2007        PMID: 17591313     DOI: 10.1097/SMJ.0b013e31804aa29f

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  13 in total

1.  High-dose immunoglobulin preparations improve survival in a CLP-induced rat model of sepsis.

Authors:  Takahisa Yoshikawa; Hiroya Takeuchi; Koichi Suda; Taku Miyasho; Shingo Yamada; Minoru Okamoto; Yoshio Kawamura; Ikuro Maruyama; Masaki Kitajima; Yuko Kitagawa
Journal:  Langenbecks Arch Surg       Date:  2011-11-25       Impact factor: 3.445

2.  Efficacy and Therapeutic Potential of Curcumin Against Sepsis-Induced Chronic Lung Injury in Male Albino Rats.

Authors:  Y-F Liu; C-W Yang; H Liu; S-G Sui; X-D Li
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

3.  A neutrophil elastase inhibitor, sivelestat, reduces lung injury following endotoxin-induced shock in rats by inhibiting HMGB1.

Authors:  Satoshi Hagiwara; Hideo Iwasaka; Kazumi Togo; Takayuki Noguchi
Journal:  Inflammation       Date:  2008-08       Impact factor: 4.092

4.  Low-dose, off-label drotrecogin alfa (xigris) in severe sepsis.

Authors:  Shan Wang; Kristina Dabovic; Ruth S Spector
Journal:  P T       Date:  2008-08

5.  High-dose intravenous immunoglobulin G improves systemic inflammation in a rat model of CLP-induced sepsis.

Authors:  Satoshi Hagiwara; Hideo Iwasaka; Akira Hasegawa; Nobuhiko Asai; Takayuki Noguchi
Journal:  Intensive Care Med       Date:  2008-05-24       Impact factor: 17.440

6.  Protective Effects of Growth Arrest-Specific Protein 6 (Gas6) on Sepsis-Induced Acute Kidney Injury.

Authors:  Long-wang Chen; Wei Chen; Zhi-qiang Hu; Jia-lan Bian; Lan Ying; Guang-liang Hong; Qiao-meng Qiu; Guang-ju Zhao; Zhong-qiu Lu
Journal:  Inflammation       Date:  2016-04       Impact factor: 4.092

7.  Portable microfluidic chip for detection of Escherichia coli in produce and blood.

Authors:  ShuQi Wang; Fatih Inci; Tafadzwa L Chaunzwa; Ajay Ramanujam; Aishwarya Vasudevan; Sathya Subramanian; Alexander Chi Fai Ip; Banupriya Sridharan; Umut Atakan Gurkan; Utkan Demirci
Journal:  Int J Nanomedicine       Date:  2012-05-29

8.  The microcirculation in sepsis.

Authors:  Asha Tyagi; Ashok Kumar Sethi; Gautam Girotra; Medha Mohta
Journal:  Indian J Anaesth       Date:  2009-06

9.  Prevalence of systemic inflammatory response syndrome (SIRS) in hospitalized children: a point prevalence study.

Authors:  Jana Pavare; Ilze Grope; Dace Gardovska
Journal:  BMC Pediatr       Date:  2009-04-03       Impact factor: 2.125

10.  Protective effects of the combination of sodium ferulate and oxymatrine on cecal ligation and puncture-induced sepsis in mice.

Authors:  Mengxin Xu; Wei Wang; Xiaokun Pei; Songmei Sun; Mingbo Xu; Zhifeng Liu
Journal:  Exp Ther Med       Date:  2014-03-05       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.